Elisabeth Gautier

Elisabeth Gautier is a Senior Director at Alterity Therapeutics. Elisabeth has over 25 years of experience in the pharmaceutical industry.

Gautier began their career at Pfizer Global R&D in 1995 as a medicinal chemist. Elisabeth quickly rose through the ranks, becoming a team leader in 1999. In this role, they were responsible for the design and synthesis of new drug candidates, as well as managing a team of scientists.

In 2002, Gautier left Pfizer to join Prana Biotechnology as a senior director. In this role, they were responsible for chemistry manufacturing and controls (CMC). During their time at Prana, they led the medicinal chemistry team and was instrumental in the discovery of new drugs.

Gautier has been with Alterity Therapeutics since 2019. In their current role as Senior Director of CMC, they are responsible for the development and implementation of CMC strategy. Elisabeth also leads the medicinal chemistry team and is responsible for the synthesis of new drug candidates.

Elisabeth Gautier has a PhD in Organic Chemistry from the University of East Anglia, and a degree in Chimie Fine et Ingenierie from the Institut national des Sciences appliquées de Rouen.

Elisabeth Gautier reports to Jim Kerr, Vice President, CMC.